Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Signs on MultiPlan for Coverage of Breast Cancer Test

NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement under which healthcare providers that participate in the network of managed healthcare plan MultiPlan will offer access to GTG's BrevaGen breast cancer test.

The deal, executed by GTG's wholly owned subsidiary Phenogen Sciences, provides the company access to MultiPlan's network of 4,800 hospitals, 99,000 ancillary facilities, and 700,000 healthcare professionals across the US. MultiPlan is headquartered in Valencia, Calif., and covers approximately 39 million lives, GTG noted.

The agreement is the sixth reached between Melbourne, Australia-based GTG and a US preferred provider organization. In total, 62 million covered lives in the US now have access to the company's BrevaGen test as an in-network service, the firm said. Earlier this month, it inked a deal with the Three Rivers Provider Network.

The DNA-based BrevaGen test evaluates the presence or absence of common SNPs associated with an increased risk for developing breast cancer.

Financial and other terms of the deal were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.